Home  |  Contact

UniProtKB/Swiss-Prot O60931: Variant p.Pro200Leu

Cystinosin
Gene: CTNS
Variant information

Variant position:  200
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Leucine (L) at position 200 (P200L, p.Pro200Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CTNSJAN; decreased cystine transport.
Any additional useful information about the variant.



Sequence information

Variant position:  200
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  367
The length of the canonical sequence.

Location on the sequence:   LLWVPYIKEQFLLKYPNGVN  P VNSNDVFFSLHAVVLTLIII
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LLWVPYIKEQFLLKYPNGVN-PVNSNDVFFSLHAVVLTLIII

Mouse                         LLWVPYIQEEFLLKYPNGVN-PVDSNDAFFSLHAVALTLIV

Bovine                        LFWVPSIKEQFLLKYPNGVN-PVDSNDVFFSLHAVALTLVV

Caenorhabditis elegans        MYYNSHVKNEYNIVNPRSPP-PVLLNDVVFAVHAFLACFIT

Drosophila                    LYFIEDLQNEYEVRYPLGVN-PVMLNDVVFSLHAMFATCIT

Slime mold                    LYFDKLVKNEYYDKY--GPPIPVQQSDIAFAIHGFVLTAIT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 23 – 367 Cystinosin
Topological domain 183 – 205 Lumenal
Mutagenesis 205 – 205 D -> N. Abolished steady-state transport current. Decreased midpoint potential.
Mutagenesis 211 – 211 H -> F. Accelerated the time course.


Literature citations

Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis.
Kalatzis V.; Cohen-Solal L.; Cordier B.; Frishberg Y.; Kemper M.; Nuutinen E.M.; Legrand E.; Cochat P.; Antignac C.;
Hum. Mutat. 20:439-446(2002)
Cited for: VARIANTS CTNS VAL-110; ARG-222; LYS-288; ASP-346--349-PHE DEL AND ASP-VAL-GLU-PHE-349 INS; VARIANTS CTNSJAN THR-177 AND LEU-200;

Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin.
Kalatzis V.; Nevo N.; Cherqui S.; Gasnier B.; Antignac C.;
Hum. Mol. Genet. 13:1361-1371(2004)
Cited for: FUNCTION; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS CTNS VAL-110; PHE-133; PHE-139; PHE-141; PRO-158; ASP-169; SER-177; ARG-182; ASN-205; ASP-205 DEL; ARG-222; SER-270 DEL; LYS-288; ASN-298; TYR-305; ARG-308; PRO-338; ARG-339; 343-ILE--ASP-346 DEL; ASP-346--349-PHE DEL AND ASP-VAL-GLU-PHE-349 INS; CHARACTERIZATION OF VARIANT CTNSJAN 67-ILE--PRO-73 DEL; PRO-CYS-SER-154 INS; LEU-200; ARG-280; LYS-323 AND ASN-346; CHARACTERIZATION OF VARIANT CTNSANN ARG-197; CHARACTERIZATION OF VARIANT ILE-42 AND ILE-260;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.